Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808819 · ClinicalTrials.gov registry record · Phase 3
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
NCT02808819 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 447 participants.
The verdict
NCT02808819, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
Study Summary
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).
Interventions
- BIOLOGICAL Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2020-06-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808819
The ClinicalTrials.gov registry entry for NCT02808819 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Benralizumab is the first listed.
NCT02808819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02808819 about?
NCT02808819 is a clinical study titled "A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist". The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA...
What is the current status of trial NCT02808819?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2016-06-30. Estimated completion is 2020-06-18.
What interventions are being tested in trial NCT02808819?
The interventions under investigation include: Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02808819?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.